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ABSTRACT 
Renovascular hypertension (RVH) caused by atherosclerotic renal artery stenosis (ARAS) is 
one of the most common forms of secondary hypertension. The prognosis for patients with 
RVH is much worse compared to patients with primary hypertension, and caused by a high 
cardiovascular morbidity. The aim of this thesis was to increase our knowledge about the 
pathophysiology of RVH and to identify novel treatment targets that could reduce 
cardiovascular risk in these patients. We investigated: 1) whether systemic inflammation and 
endothelin-1 (ET-1) are increased in patients with RVH and evaluated how treatment with 
percutaneous transluminal renal angioplasty (PTRA) affected these variables; 2) lipoprotein 
abnormalities in patients with atherosclerotic renovascular disease (ARVD) and analyzed 
whether angiotensin II (Ang II) receptor antagonism with candesartan influenced lipoprotein 
levels; 3) whether plasma levels of brain natriuretic peptides (BNP) are increased in patients 
with ARAS and may predict favorable outcome of PTRA; and 4) the long-term effects of 
candesartan on kidney function, inflammatory biomarkers and ET-1 in patients with ARVD 
and residual hypertension after PTRA.  
In patients with significant renal artery stenosis (RAS) we found increased plasma levels of 
inflammatory biomarkers and ET-1 compared to healthy subjects. Intervention with PTRA 
triggered a rapid, transient increase in hs-CRP and IL-6. However, one month after PTRA, 
both IL-6 and ET-1 had decreased compared to before intervention. Patients with ARVD had 
elevated levels of atherogenic, triglyceride-rich, ApoC-III-containing lipoproteins in spite of 
ongoing treatment with statins. Treatment with candesartan did not correct these abnormalities. 
Patients with ARAS had increased plasma levels of BNP compared to healthy controls, but 
BNP concentrations were not affected by PTRA. Plasma levels of BNP could not be used to 
predict the outcome of PTRA on blood pressure. Candesartan did not have any significant 
effects on kidney function, inflammatory biomarkers or ET-1 in patients with ARVD during 
35 months of follow up.   
In conclusion, patients with ARAS had increased levels of inflammatory biomarkers, ET-1, 
and ApoC-III-containing lipoproteins that may contribute to progressive atherosclerosis and 
accelerated cardiovascular disease. Intervention with PTRA reduced plasma levels of IL-6 and 
ET-1 indicating beneficial effects on inflammation and the endothelin system. Plasma 
concentrations of BNP could not be used to identify patients with a favorable outcome to 
PTRA.  
Keywords: inflammation, endothelin-1, apolipoprotein C-III, brain natriuretic peptides, 
angiotensin II receptor antagonism, renal angioplasty, renovascular hypertension, 
atherosclerotic renal artery stenosis  
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 POPULÄRVETENSKAPLIG 
SAMMANFATTNING PÅ SVENSKA 
Förträngning av njurartären (njurartärstenos) är orsak till högt blodtryck 
(hypertoni) upp till 5% av alla patienter med hypertoni. Den vanligaste 
orsaken till att en förträngning uppstår är åderförkalkningssjukdom 
(ateroskleros). Prognosen för patienter med njurartärstenos (NAS) är 
betydligt sämre än för patienter med primär hypertoni och är associerad med 
hög hjärt-kärl sjuklighet och dödlighet. Minskning av blodtillförseln till 
njuren leder till aktivering av  renin-angiotensin-aldosteron systemet (RAAS) 
som bidrar till att höja blodtrycket. Orsaken till den höga hjärt-kärl 
sjukligheten hos dessa patienter är inte helt klarlagd. Vi tror att riskfaktorer 
som inflammation, och specifika blodfettsrubbningar, sekundära till 
aktivering av RAAS eller nedsatt njurfunktion, ligger bakom en accelererad 
åderförkalkning. Trots ballongvidgning (PTRA) av förträngningen och 
förbättrat blodflöde till njuren är det tveksamt om PTRA förbättrar 
njurfunktionen och minskar hjärt-kärlhändelser.  Angiotensin II (Ang II), 
som är den aktiva substansen i RAAS, stimulerar också produktion av brain 
natriuretic peptide (BNP), ett hormon som frisätts från hjärtmuskelceller och 
som motverkar Ang II:s blodtryckshöjande effekter.  
Den övergripande målsättningen med detta arbete var att öka kunskapen om 
patofysiologin vid NAS och att förbättra behandlingen och minska risken för  
hjärt-kärlinsjuknande. Vi studerade om inflammation är ökad vid NAS och 
hur intervention med PTRA påverkade inflammationsmarkörer. Vidare 
undersökte vi blodfettsprofilen hos patienter med NAS och undersökte om 
behandling med candesartan, som blockerar RAAS systemet, påverkade 
denna. Sedan undersökte vi om BNP är förhöjt hos patienter med NAS och 
om BNP kunde användas för att identifiera patienter som har klinisk nytta av 
PTRA. I sista arbetet analyserade vi långsiktiga effekter av candesartan på 
njurfunktion och inflammation hos patienter med NAS. 
Arbetet baseras på en prospektiv, randomiserad, öppen studie, där vi 
studerade effekterna av candesartan på patienter med aterosklerotisk NAS 
som genomgått behandling med PTRA under år 2003-2008. Vi inkluderade 
178 patienter med misstänkt NAS, varav 108 genomgick PTRA. Fyra veckor 
efter PTRA randomiserades patienter med kvarstående hypertoni (>130/80 
mmHg) antingen till candesartan eller till antihypertensiv behandling utan 
RAAS-blockerare. Patienterna följdes upp i 3 år efter PTRA.  
Vi fann att patienter med signifikant NAS hade förhöjda 
inflammationsmarkörer jämfört med friska kontroller. PTRA åstadkom en 
snabb övergående ökning av  inflammationsmarkörer. En månad efter PTRA 
hade vissa av de markörerna sjunkit till en lägre nivå än innan 
ballongvidgning tydande på en gynnsam effekt av PTRA. Vi fann också att 
patienter med NAS har en särskilt farlig rubbning i blodfetterna trots 
behandling med kolesterolsänkande läkemedel. Candesartan påverkade inte 
blodfettsbilden under 11 månaders behandling efter PTRA. Vår studie visade 
att BNP var signifikant förhöjt hos patienter med NAS jämfört med friska 
kontroller, men inte påverkades av PTRA. Studien ger inget stöd för 
användning av BNP-analyser för att identifiera patienter som kommer att ha 
nytta av PTRA. Vår hypotes var att candesartan kunde ha njurskyddande och 
antiinflammatoriska effekter. Resultaten visade att candesartan inte 
påverkade njurfunktion, eller inflammatoriska markörer under 35 månaders 
behandlingstid hos patienter med NAS, som genomgått PTRA. Candesartan  
tolererades dock väl utan njurbiverkningar.  
                                                                                                                                                            
Sammanfattningsvis visade vår studie att patienter med NAS har ökad 
inflammation jämfört med friska individer samt en särskilt farlig blodfettsbild 
trots statinbehandling. Dessa avvikelser skulle kunna bidra till snabb 
utveckling av åderförkalkning och en accelererad hjärt-kärlsjukdom. Det 
krävs fler studier med ett större antal patienter samt längre uppföljningstid för 
att undersöka vilka kliniska konsekvenser dessa rubbningar kan ha. Vår 
studie visar att PTRA kan ha gynnsam effekt på inflammation även om 
ingreppet ger upphov till en övergående inflammatorisk svar. BNP kan inte 
användas för att forutsäga vilka patienter som har klinisk nytta av PTRA. Hos 
patienter med NAS som genomgått PTRA kunde vi inte påvisa någon 
antiinflammatorisk effekt av candesartan, men den var väl tolererad utan 
njurbiverkningar och kan användas med säkerhet hos denna patientgrupp.
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1 INTRODUCTION 
1.1 The kidneys 
The kidneys exert a variety of homeostatic functions through their capacity to 
regulate the content of water and electrolytes in the body fluids. The kidneys 
also remove waste products, maintain acid base balance, regulate blood 
pressure and synthesize hormones such as erythropoietin, active vitamin D 
and renin. The present thesis focuses on the role of the kidneys in blood 
pressure regulation.  
1.1.1 Renin-angiotensin-aldosterone system in blood 
pressure regulation 
The kidneys control blood pressure (BP) through multiple mechanisms. 
Already in 1898 Tigerstedt and Bergman [1] described the occurrence of 
renin, a BP-raising substance from rabbits renal cortex. The role of renal 
artery stenosis in the development of renovascular hypertension was clarified 
by Goldblatt in 1934 [2] who demonstrated that reduced perfusion of the 
kidney produced a sustained elevation of BP. Later work identified activation 
of the renin-angiotensin-aldosterone system (RAAS) as a central component 
of this process [3, 4]. Reduced pressure in afferent renal arterioles  is sensed 
by juxtaglomerular cells  resulting in the release of the enzyme renin [5]. 
Renin then acts upon circulating angiotensinogen to produce angiotensin I 
which is subsequently converted to angiotensin II (Ang II) by the action of 
angiotensin converting enzyme (ACE). Renin release is considered to be the 
rate-limiting step in the RAAS cascade. Angiotensin II, the main effector 
peptide of the RAAS, raises BP by multiple mechanisms. For instance, Ang 
II causes arterial vasoconstriction and increases total peripheral resistance, 
stimulates secretion of aldosterone from the adrenal glands, potentiates the 
sympathetic nervous system, enhances thirst, and triggers release of 
antidiuretic hormone [6]. Angiotensin II also blunts the pressure-natriuretic 
respons to elevated BP.    
1.2 Renovascular hypertension 
Hypertension is defined as BP ≥140/90 mmHg. Hypertension is an important 
risk factor for cardiovascular disease, stroke and renal failure. Renovascular 
hypertension (RVH) is defined as hypertension induced by renal artery 
Cardiovascular risk factors in renal artery stenosis 
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stenosis (RAS) which causes decreased renal perfusion and an activated 
RAAS. 
1.2.1 Epidemiology of renal artery stenosis 
Renovascular hypertension is one of the most common forms of secondary 
hypertension and occurs in 1-5% of all patients with hypertension [7]. 
However, the true prevalence is hard to estimate given the asymptomatic 
nature of majority of cases. The prevalence may be considerably higher in 
specific patient groups. In resistant hypertension the prevalence may be 15-
20% [8]. The prevalence increases with age [9] and is higher in patients with 
established cardiovascular diseases (CVD), e.g. coronary artery stenosis, 
congestive heart failure or peripheral vascular disease [10-16]. For example, 
the prevalence of renal artery stenosis in patients with coronary artery 
stenosis undergoing coronary angiography is 15-19% [10, 16]. No racial 
differences have been reported in the prevalence of RAS [17].  
Etiology of RAS  
There are two main causes of RAS: atherosclerosis and fibromuscular 
dysplasia (FMD). In Western populations, atherosclerosis is the leading cause 
of RAS, constituting up to 90% of the cases [18, 19]. The stenosis is typically 
located either in the ostium or in the proximal segment of the renal artery and 
may be unilateral or bilateral. The frequency increases after 50 years of age 
and males are more commonly affected than females. Atherosclerotic RAS 
(ARAS) is usually a manifestation of generalized atherosclerosis. In 
approximately 10% of cases, RAS is caused by FMD, which is more frequent 
in women and with a highest incidence in the age 25- to 50- years. The right 
renal artery is more commonly affected and the changes are located distally. 
Fibromuscular dysplasia may occur simultaneously in other vascular beds 
(e.g. carotid, vertebral, iliac, subclavian, visceral and coronary arteries) [7, 
18, 19]. The etiology of FMD is unknown, but a number of factors have been 
suggested, such as genetic predisposition, hormonal influence, mechanical 
factors (stretching and trauma to the blood vessel wall), and ischemia of the 
vascular wall due to fibrotic occlusion of the vasa vasorum [18, 19]. Less 
frequent causes of RAS include vasculitis (e.g. Takayasu's arteritis), aortic 
dissection, renal artery aneurysm, arterio-venous fistula and antiphospholipid 
syndrome.  
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1.2.2 Pathophysiology of renovascular hypertension 
Renin-angiotensin-aldosterone system   
Renal artery stenosis is an anatomical narrowing of the artery lumen, but this 
does not in itself embrace the existence of its pathophysiological 
consequences i.e. hypertension and reduced renal function. For a stenosis to 
affect renal blood flow or perfusion pressure resulting in the release of the 
renin a reduction of at least 75% of the cross-sectional area of the vessel is 
required. This corresponds to a reduction of the blood vessels diameter by 
50% [20, 21]. Some studies show that also a pressure gradient across the 
stenosis is required to cause renin release. This occurs when a pressure distal 
to the stenosis is reduced at least 10-20% below the pressure (AP) in aorta. 
This corresponds to a trans-stenotic mean arterial pressure gradient (MAPG) 
of at least 10-20 mmHg [20, 22].   
In unilateral RAS, the contralateral non-stenotic kidney responds to the 
elevated BP by increasing sodium excretion (i.e. pressure-natriuresis). 
Hypertension in this condition is Ang II dependent. In bilateral RAS, or when 
a RAS is present to a solitary kidney, there is no non-stenotic kidney to 
excrete sodium and water in response to increased BP. Hypertension in this 
situation is due mainly  to volume expansion, which finally leads to feedback 
inhibition of the RAAS. In this setting hypertension is considered Ang II 
independent [5].  
1.2.3 The clinical manifestations of RAS 
The RAS activates the RAAS resulting in hypertension and also often 
decreased glomerular filtration rate (GFR). RAS is a progressive disease and 
causes a spectrum of clinical syndromes ranging from asymptomatic lesion 
(“incidental RAS”), by symptomatic RAS (renovascular hypertension) to 
more advanced disease as ischemic nephropathy with decreased GFR and 
accelerated cardiovascular disease [5]. Many patients with ARAS have years 
of preexisting primary hypertension, active smoking histories and coexisting 
diabetes mellitus [16]. 
The deterioration of renal function in RAS 
The pathophysiological mechanisms leading to decreased GFR in patients 
with RAS are multiple, complex and not clearly understood. The term 
“ischemic nephropathy” has been commonly used to describe the impairment 
in renal function beyond an occlusive disease of the main renal artery [5, 23]. 
It is defined as an obstruction of renal blood flow that leads to ischemia and 
excretory dysfunction. Histologically, it is characterized by arteriolar 
Cardiovascular risk factors in renal artery stenosis 
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nephrosclerosis, collapsed glomeruli and interstitial fibrosis, therefore the 
picture is unspecific [23]. The injury of the stenotic kidney may be induced 
by the activation of vasopressor systems such as the RAAS and ET-1, in 
addition to a direct damaging effect of hypoxia [5, 23]. The pre-existing long-
term primary hypertension in this patient group may also contribute to renal 
injury. Interestingly, FMD rarely results in impaired renal function despite 
similar degrees of stenosis compared with ARAS. This observation suggests 
that atherosclerosis and comorbidity play an important role in kidney damage 
in RVH [23].  
When to suspect RAS in the hypertensive patient? 
The typical clues to suggest the diagnosis RVH include: 1) treatment resistant 
hypertension (>140/90 mmHg) despite 3 or more antihypertensive drugs in 
the maximum dose, 2) treatment failure, accelerated (previously well-
controlled hypertension, which suddenly becomes difficult to treat), or 
malignant hypertension, 3) severe hypertension in a young individual (<30 
years in males and <50 years in women), 4) severe hypertension and 
progressive deterioration of renal function of unknown origin, 5)  
hypertension associated with reduced renal function or worsening of renal 
function during treatment with RAAS-blockers, 4) unexplained asymmetry in 
renal size, or 5) recurrent pulmonary edema associated with hypertension 
[18]. 
1.2.4 Screening methods 
The first-hand screening tests for RAS are color duplex sonography (CDS), 
magnetic resonance angiography (MRA) and computed tomography 
angiography (CTA). These methods have similar sensitivity and specificity.  
The choice of method can be determined in part from local competence and 
tradition. 
Color duplex sonography 
Doppler ultrasound is a safe, inexpensive non-invasive screening test for 
RAS and provides high sensitivity and specificity (80-95%) in experienced 
laboratories [24]. The other advantage of this method is that patients avoid 
exposure to radiation or contrast and can be used in patients with renal 
failure. This method can provide reliable hemodynamic assessment of arterial 
stenosis [25], which is important to know before making a decision about 
revascularization. The limitation of this approach is that its diagnostic 
accuracy depends on the investigator's experience and the patient's body 
characteristics. Using this method blood flow is tested at the renal hilum and 
in the intraparenchymal renal arteries. Furthermore, measurement of 
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intrarenal resistive index (RI) can indicate small vessels disease. Rademacher 
et al suggested a RI of ≥ 0.80 as a negative predictor for clinical outcome 
after revascularization since a RI of ≥ 0.80 associated with reduced   
likelihood of improved BP or renal function by PTRA [26].  However, these 
results were not confirmed in other studies [27]. 
Magnetic resonance angiography   
Magnetic resonance angiography with gadolinium contrast provides good 
morphological information about the aorta and other abdominal blood vessels 
including renal arteries. It has a high sensitivity (around 95%) and specificity 
(around 90%) for detecting proximal RAS, but lower sensitivity in detecting 
stenotic lesion in the middle and distal part of renal artery. Therefore, MRA 
is a very useful method for screening atherosclerotic RAS but has limited 
value in diagnosing FMD [5, 24]. The limitation of this method is the risk of 
nephrogenic systemic fibrosis caused by gadolinium-based contrast agents in 
patients with severe renal failure. Furthermore, MRA may overestimate the 
degree of stenosis.  
Computed tomography angiography 
Computed tomography angiography provides similar diagnostic accuracy as 
MRA with the same sensitivity and specificity [5, 24]. It is a better method to 
follow up patients with stent. Limitations include exposure to the radiation 
and the risk of contrast nephropathy with reduced renal function.  
ACE inhibitor renography 
It is a functional screening test, which is performed by intravenously injected 
isotope, which is excreted by glomerular filtration and/or tubular secretion.   
Renal uptake of the isotope is recorded by a gamma camera. The procedure is 
performed before and after an oral dose of the angiotensin converting enzyme 
inhibitor (ACEI) captopril. If the side difference between renal uptake is 
more pronounced after ACEI, a significant RAS is considered to be present. 
The sensitivity and specificity of ACEI renography is in the range of 85% 
[24]. However, this procedure is much less sensitive and specific in patients 
with bilateral RAS, impaired renal function, urinary obstruction, and chronic 
intake of ACEI [24] and therefore is less suitable for this patient group. This 
method is not recommended as the first-hand test.  
The goal of the further investigation should be an aim at receiving the 
appropriate decision concerning whether the patient in question should be 
subject to revascularization or not. If the initial screening was performed with 
a CDS it is wise to complement this investigation with a CTA or a MRA-
examination to delineate the vascular anatomy before the renal angiography 
Cardiovascular risk factors in renal artery stenosis 
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is done. Conversely, it is valuable to complement a CTA or a MRA-
examination with a CDS investigation to prove that the stenosis is 
hemodynamically significant.  
 
1.2.5 Digital subtraction angiography 
Renal angiography (digital subtraction angiography) is the gold standard in 
diagnosis of RAS. This method gives a good morphological assessment and 
by measuring the trans-stenotic arterial pressure gradient it is also possible to 
assess the hemodynamic impact of the stenosis [28]. A trans-stenotic pressure 
gradient of at least 20 mmHg in systolic AP, or at least 10 mmHg in mean 
arterial pressure (MAPG), has been used to determine whether a stenosis is 
hemodynamically significant [20, 22]. The advantage of this method is the 
ability to perform a therapeutic intervention by percutaneous transluminal 
renal angioplasty (PTRA) during the same séance. Some data indicate that a 
MAPG ≥ 10 mmHg is able to predict those patients with RAS responding to 
PTRA with reduced  BP or a reduced need for antihypertensive drugs [29]. 
This method is the gold standard, but is expensive and its use is limited by 
the invasive nature of the procedure. It is also associated with some risks and 
the potential adverse effect of intravenous contrast.  
1.2.6 Management of renovascular hypertension 
Management of RVH involves both an invasive treatment as PTRA and a 
non-invasive medical therapy depending on etiology and degree of 
comorbidity.  
Treatment of fibromuscular dysplasia of the renal arteries 
The primary treatment of patients with RVH caused by FMD is PTRA, since 
a meta-analysis has shown that almost half of the patients are cured by the 
procedure and the majority of the remaining patients obtain an improved AP 
control [30]. 
Treatment of atherosclerotic renal artery stenosis 
The management of atherosclerotic RAS in patients with hypertension or 
impaired renal function remains a clinical dilemma. It is still unclear if 
restoring vessel patency by PTRA in ARAS improves outcomes in these 
patients [18]. Our study was initiated in 2003, i.e. before the publication of 
two large randomized clinical trials the ASTRAL [31] and the CORAL [32]. 
These studies have been performed in patients with ARAS, where PTRA plus 
medical treatment has been compared to medical treatment only. Variables in 
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the studies have been changes in BP and renal function and a combination of 
renal and cardiovascular outcomes. The results of these studies show that 
PTRA is not advantageous over medical treatment. In addition, PTRA 
procedure was associated with substantial serious complications. The 
conclusion of these studies was that the majority of patients with ARAS 
should not be further investigated and revascularized but be subjected to 
aggressive medical treatment. Maybe revascularization could be indicated in 
special groups of ARAS patients.  
Medical management 
Aggressive antihypertensive treatment plays an elemental role in medical 
management of all patients with RVH independent of the patient will be a 
candidate for revascularization or not. Previously, RAAS blockade in patients 
with RVH was considered contraindicated due to fear of inducing renal 
ischemia [33, 34]. At present, pharmacological blockade of the RAAS with 
either ACEI or ARB (angiotensin II receptor antagonist) is considered a first-
line therapy in RVH to counteract activation of RAAS [35-38]. Patients with 
RVH often have other indications for ACEI and/or ARB treatment in 
addition to hypertension, as diabetes, congestive heart failure, or high 
cardiovascular risk. Clinical data show that RAAS blockers may reduce the 
risk of cardiovascular events and reduce mortality in ARAS patients and can 
be used in this patient group without risks [35-37]. However, it needs to be 
remembered, that these agents may accelerate the damage to the stenotic 
kidney. Therefore RAAS blockade should not be used in patients with 
bilateral RAS or stenosis of a solitary kidney. However, these patients may 
be considered for revascularization [5, 18].  
Atherosclerotic RAS represents a clinical manifestation of atherosclerotic 
disease, and is often associated with hyperlipidemia and smoking. Therefore, 
the use of cholesterol lowering therapy by statins, antiplatelet agents and life 
style modifications such as smoking cessation, reduced dietary intake of salt 
and increased exercise are paramount to reduce these risks [39]. 
Renal revascularization  
Interventional treatment of renal artery stenosis includes PTRA with or 
without stent placement and in some rare cases surgery. Endovascular 
therapy became implemented in 1978 [40] and has developed a lot since then 
and has replaced surgery [41]. It has been shown that PTRA with stenting are 
more efficacious than PTRA without stent regarding restenosis and improved 
technical success [42].   
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1.3 Cardiovascular morbidity in patient with 
atherosclerotic renal artery stenosis 
The prognosis of RVH is much worse than for patients with primary 
hypertension, and is associated with high cardiovascular morbidity and 
mortality [43, 44]. The mortality in this patient group is increased six-fold 
compared to an age-matched population [43]. Renal artery stenosis is a 
common manifestation of atherosclerosis and is frequently associated with 
other atherosclerotic diseases such as coronary artery disease, 
cerebrovascular disease, and peripheral vascular disease [35, 45-53]. In 
addition, the presence of RAS is a strong independent predictor of mortality, 
and increasing severity of RAS has an incremental effect on mortality in 
patients undergoing coronary angiography [54]. 
Renal artery stenosis not only gives rise to activation of RAAS resulting in 
hypertension, but also to a decrease in renal function [55, 56]. Both 
hypertension, activation of the RAAS, and renal insufficiency are known 
cardiovascular risk factors [52, 57, 58] (Figure 1).   
 
 
 
 
  
        
Figure 1.The clinical manifestations of renal artery stenosis.  Abbreviations are: GFR,    
glomerular filtration rate; RAAS, renin-angiotensin-aldosterone system. 
The reason for the increased cardiovascular (CV) morbidity and mortality in 
patients with renovascular hypertension is not clearly understood. It is 
reasonable to speculate that the high CV risk in this patient group is most 
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likely multifactorial and the other additional, non-traditional risk factors may 
contribute to the high CV morbidity and mortality in this patient group.  
Angiotensin II may contribute to hypertension and end-organ damage by 
triggering a number of downstream effector pathways [5]. These proposed 
mechanisms include increased inflammation and oxidative stress, enhanced 
endothelin 1 (ET-1) production, and arterial wall re-modeling [5] (Figure 2).  
In addition, Ang II has been shown to increase the oxidation of low-density 
lipoprotein cholesterol, metallo-proteinase production, and lipid peroxidation 
[59-61].  
 
 
Figure 2. Schematic illustration of pressor mechanisms identified in renovascular 
hypertension. Abbreviations are : LV, left ventricle; (Modified from: Garovic VD et 
al. Renovascular hypertension and ischemic nephropathy. Circulation 2005; 
112:1362-74). 
 
1.3.1 Additional mechanisms in renovascular 
hypertension 
Endothelin-1 
Angiotensin II stimulates the synthesis of  ET-1, a potent  vasoconstrictor and 
pressor peptide produced by vascular endothelial cells [62] which is involved 
in the initiation and progression of atherosclerosis [63]. The biological 
actions of  ET-1 are mediated via two receptors: type A (ETA) and type B 
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(ETB) [64]. In the kidney, ET-1 exerts direct effects on tubular epithelial cells 
by ETA and/or ETB receptors and regulates sodium and water reabsorption 
[65]. In addition, ET-1 influences salt and water homeostasis also through its 
effects on the RAAS, vasopressin and atrial natriuretic peptide and stimulates 
the sympathetic nervous system [66]. The physiological actions of ET-1 
relevant to cardiovascular disease take place in various organs, such as: the 
systemic vascular bed, the pulmonary vascular bed, the heart, the kidney, and 
the endocrine system [66].  
Inflammation 
At the molecular and cellular levels, Ang II stimulates key components of 
atherosclerosis [67]. Atherosclerosis is a chronic inflammatory disease, 
which involves vascular cells, immune system, and several organs [68]. The 
RAAS serves an important role in promoting inflammation [67, 69]. 
Impairment of the endothelium is the first physiological alteration in the 
pathophysiology of atherosclerosis which is manifested by enhanced vascular 
constriction triggered by Ang II and endothelin. Furthermore, Ang II induces 
the production of reactive oxygen species, inflammatory cytokines, and 
adhesion molecules [70]. Therefore, inflammatory processes are manifested 
by increased biosynthesis of mediators of inflammation and thrombosis [71]. 
Several inflammatory mediators such as tumor necrosis factor-α (TNF-α) 
[72], neopterin [73], interleukin-6 (IL-6) [74], and CD40 ligand  (CD40L) 
[75, 76] are involved in atherogenesis. In particular, increased levels of IL-6 
and high-sensitivity C-reactive protein (hs-CRP) have been shown to predict 
cardiovascular disease [77].  
Dyslipidemia 
In patients with ARAS, dyslipidemia could be a primary event leading to the 
development of peripheral stenotic lesions involving renal arteries. However, 
dyslipidemia can also develop as a consequence of reduced GFR (i.e. renal 
dyslipidemia) [78] and may thus be superimposed on atherosclerotic 
renovascular disease (ARVD). Notably, renal dyslipidemia is not always 
reflected in hyperlipidemia but in altered concentrations of individual 
lipoprotein subclasses classified according to their apolipoprotein (Apo) 
composition [79-81]. Renal dyslipidemia is characterized by the 
accumulation of atherogenic ApoB- and ApoC-containing lipoproteins [80, 
81] and could hence add to pre-existing perturbations of lipoprotein 
metabolism. The classification system of lipoproteins recognizes two classes, 
one of which is characterized by ApoA and the other by ApoB as the major 
lipoprotein constituents (Figure 3). The former lipoprotein class consists of 
two major lipoprotein subclasses, lipoprotein A-I (LpA-I) and lipoprotein A-
I:A-II (LpA-I:A-II), whereas the latter encompasses five major subclasses 
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called lipoprotein B (LpB), lipoprotein B:E (LpB:E), lipoprotein B:C 
(LpB:C), lipoprotein B:C:E (LpB:C:E), and lipoprotein A-II:B:C:D:E 
(LpAII:B:C:D:E) [79, 82]. In addition to their unique apolipoprotein 
composition, each of these lipoprotein subclasses has specific metabolic and 
functional properties [79, 82]. Furthermore, previous studies have indicated 
that ApoB-containing lipoprotein subclasses may differ in their atherogenic 
capacities [79, 83, 84] and ApoA-containing lipoproteins in their 
antiatherogenic potentials [79, 85-87]. While lipoprotein subclasses have 
been analysed in detail in patients with chronic kidney disease (CKD) [80, 
81, 88, 89], such analyses have to our knowledge not been carried out in 
patients with ARAS.  
 
Figure 3.The normal lipoprotein metabolism and the concept of lipoprotein particles. A 
lipoprotein particle consists of a core of lipids, predominantly triglycerides and 
cholesterol esters. On the surface, the particles have proteins of specific types, 
apolipoproteins with different functions. These apolipoproteins determine the metabolic 
function of the individual particle. TG, triglycerides; CE, cholesterol ester; A, 
apolipoprotein A; B, apolipoprotein B; C, apolipoprotein C; E, apolipoprotein E. 
(Modified from:Per-Ola Attman and Ola Samuelsson. Dyslipidemia of kidney disease. 
Current Opinion in Lipidology 2009,20:293-9). 
 
Brain natriuretic peptide in ARAS 
Brain natriuretic peptide (BNP) belongs to the vasoactive peptides that are 
synthesized, stored, and secreted from the ventricular myocytes in response 
to atrial or ventricular stretch [90] in the setting of volume expansion or 
pressure overload and neurohormonal activation [91]. Brain natriuretic 
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peptide is produced as prohormone (pro-BNP) which is cleaved to two parts 
during secretion: (1) the active hormone BNP and (2) the inactive hormone 
with the N-terminal part NT-proBNP. Both BNP and NT-proBNP are 
secreted in equimolar amounts during hemodynamic and neurohormonal 
stress of the heart [92]. Because of their close correlation with the severity of 
symptoms they have been developed as markers of heart failure [93, 94]. The 
elimination of these two parts differs. Serum half-life of BNP is 20 minutes 
[95], while the corresponding value for NT-proBNP is 120 minutes. Both 
BNP and NT-proBNP plasma concentrations increase in renal failure. 
Clearance of NT-proBNP is likely more dependent on glomerular filtration 
and increases more than BNP in response to renal failure [96, 97]. The most 
important physiological actions of BNP take place in the kidney where it 
exerts natriuretic and diuretic effects, causes renal vasodilation, increases 
glomerular filtration rate and inhibits renin release [98]. Hence, BNP 
counteracts the RAAS.  In addition, in vitro data have demonstrated that Ang 
II may directly induce the synthesis and release of BNP [99]. Hence, plasma 
BNP may be increased in patients with RVH at least partly due to an 
enhanced activity of the RAAS [99-101].  
 
Adiponectin in ARAS 
Overweight and obesity lead to adverse effects on AP, lipids and insulin 
resistance and a great part of cardiovascular disease could be accounted for 
this [102]. The adipose tissue is not a passive energy depot, but in fact an 
active endocrine organ secreting a variety of hormones, i.e. adipokines. 
Dysregulation of these adipokines is believed to be important for the 
development in cardiovascular disease in obesity [103]. One of these 
adipokines, adiponectin was identified as a 244 amino acid protein in 1996 
[104]. It is highly expressed and actively secreted by adipocytes and is 
present in human plasma [104]. Adiponectin has a variety of protective 
functions and is believed to exert anti-inflammatory, anti-atherogenic, and 
anti-diabetogenic effects [105]. It is reasonable to speculate that patients with 
ARAS may have reduced plasma levels of adiponectin that could contribute 
to the increased cardiovascular risk.  
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2 AIMS 
The overall aim of this study was to increase our knowledge about the 
pathophysiology of RVH and to identify novel treatment targets that could 
reduce cardiovascular risk in this patient group.  
The specific aims of the papers included in this thesis were: 
Paper I                                                                                               
To examine whether systemic inflammation and ET-1 are increased in 
hypertensive patients with RAS and to evaluate how treatment with PTRA 
affected these variables 
 
Paper II 
To investigate lipoprotein abnormalities in patients with ARVD who had 
undergone PTRA and to analyze whether Ang II receptor antagonism 
influenced lipoprotein levels  
 
Paper III 
To evaluate whether plasma levels of BNP are increased in patients with 
ARAS and may predict a favorable outcome of PTRA  
 
Paper IV 
To analyze the long-term effects of Ang II receptor antagonism on kidney 
function and inflammatory biomarkers in patients with ARVD and residual 
hypertension after PTRA 
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3 PATIENTS AND METHODS 
3.1 Patients  
All patients were recruited from the (CAndesartan in RenaL Artery Stenosis- 
CARLAS) study program, a randomized, open, investigator-initiated  trial in 
which the effects of the ARB, candesartan, was examined in patients with 
ARVD who had undergone treatment with PTRA with or without stenting. 
This study was carried out at two Swedish centers (Department of 
Nephrology at Sahlgrenska University Hospital in Gothenburg, and 
Department of Vascular Diseases at Malmö University Hospital). Between 
2003 and 2008, 178 patients at these centers, undergoing renal angiography 
for suspected RAS were considered for this study.  
Indications for renal angiography were hypertension (accelerated, refractory, 
malignant or with intolerance to medication), or a progressive increase in 
plasma creatinine concentrations (unexplained or during treatment with an 
ACEI or ARB, or recurrent hypertensive pulmonary oedema, together with a 
positive screening test for RAS as (a) duplex ultrasonography showing delta-
resistive index (RI) >0.05 with lower RI at the stenotic side, or systolic pulse 
acceleration <2.3m/s², or (b) CT-angiography, or MR-angiography indicating 
≥ 50% diameter stenosis. The exclusion criteria are shown in Table 1.  
Table 1. Exclusion criteria  
Renal size < 7.5 cm at the stenotic side    
Age > 80 years  
Pregnancy or nursing 
CKD stage 5 (eGFR< 15ml/min/1.73m²) 
RAS of other etiology than atherosclerosis  
Urinary albumin excretion > 1g/day 
Diabetes mellitus with urinary albumin excretion > 0.3g/day 
Congestive heart failure 
Strong indicated treatment with ACEI and/or ARB and/or aldosterone receptor antagonist 
Contraindication for renal angiography/angioplasty (e.g. serious contrast allergy) 
Other form of secondary hypertension 
Malignant disease  
Treatment with immune modulating drugs, e.g. cyclosporine or oral steroids 
 
CKD, chronic kidney disease;  eGFR, estimated glomerular filtration rate according to the 4-
variable equation from the Modification of Diet in Renal Disease (MDRD) study; RAS, renal 
artery stenosis ; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin II receptor 
blocker. 
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A significant RAS was defined as a lesion with a trans-stenotic MAPG of at 
least 10 mmHg, or >50 % diameter stenosis on angiography in those cases in 
which the MAPG was not measured because of technical difficulties due to 
high-grade stenosis and luminal occlusion during the procedure. One hundred 
and eight patients with significant RAS underwent angioplasty, whereas 70 
patients had no significant RAS and were therefore only subjected to the 
diagnostic procedure.  
Sixty-three patients with residual hypertension (office BP >130/80 mmHg) 
four weeks after PTRA underwent randomization to antihypertensive 
treatments based on either the ARB candesartan (ARVD-CAN, n=33) or a 
regimen without direct inhibitors of the RAAS (ARVD-C, n=30), i.e. ACE 
inhibitors, ARBs, renin inhibitors or aldosterone receptor antagonists. The 
randomization procedure was carried out by the use of sequentially 
numbered, opaque sealed envelopes. The targeted candesartan dose was 16 
mg daily and the trough BP goal was <140/90 mmHg. All patients had 
discontinued treatment with direct inhibitors of the RAAS and had been on 
HMG-CoA reductase inhibitor (i.e. statin) therapy for at least two weeks 
prior to PTRA. One-two days before angiography all patients who had no 
antiplatelet therapy were started on either acetylsalicylic acid (ASA) or 
clopidogrel. The patients were followed up for 3 years after PTRA (see study 
flow chart in figure 4). 
 
 
 
 
 
 
 
 
Figure 4. Study flow chart. Eligible individuals were patients with a clinical 
suspicion of atherosclerotic renal artery stenosis (RAS) together with a positive 
diagnostic screening test (see above). Abbreviations are: PTRA, percutaneous 
transluminal renal angioplasty; ARVD, atherosclerotic renovascular disease; ARVD-
C, control group; ARVD-CAN, candesartan group.  
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In this thesis patient data from both centers were included in paper I. In 
papers II-IV only patients from Sahlgrenska University Hospital were 
included as the number of patients randomized in Malmö was small. 
3.1.1 Patients and protocol paper I 
In this study 100 consecutive patients that fulfilled the inclusion criteria 
underwent renal angiography. 61 patients had significant RAS and underwent 
PTRA, whereas 39 patients had no significant RAS and were only subjected 
to the diagnostic procedure. A population-based control group of 219 healthy 
individuals (median age 68 years, 117 women and 102 men) from a follow-
up program for the Preventive medicine project in Malmö [106], without 
symptomatic cardiovascular disease or hypertension, was analyzed for 
comparison of inflammatory biomarkers. Office BP measurements, routine 
laboratory markers and plasma levels of inflammatory biomarkers and ET-1 
were measured immediately before, and 1 day and 4 weeks after PTRA.  
3.1.2 Patients and protocol paper II 
In this study we investigated abnormalities in a subgroup of 42 ARVD 
patients at the time of randomization 4 weeks after PTRA. These patients 
were selected as they were the only participants with a sufficient amount of 
appropriately collected and stored plasma for lipid analyses. All patients had 
been on treatment with statins at least 6 weeks before randomization. This 
treatment was maintained unaltered throughout the study period. Following 
randomization to group ARVD-CAN (n=21) or group ARVD-C (n=21), 
patients were followed for 11 month at which time point new lipid analyses 
were carried out. Lipid analyses were performed in 32 of 42 patients at 11 
month (16 patients from each group) due to 3 deaths, 2 individuals ended 
their participation, and in 5 patients there was an insufficient amount of 
plasma. In addition, 20 age-matched healthy subjects from the general 
population without any medications were examined at one time point and 
served as controls.  
3.1.3 Patients and protocol paper III 
Ninety-one patients with hypertension and suspected RAS were included in 
this study and underwent renal angiography. Angioplasty was carried out on 
47 patients with significant atherosclerotic stenosis (ARAS-group). Forty-
four individuals had no significant RAS and were subjected only to 
diagnostic angiography (non-RAS group). All patients were subjected to 
baseline measurements one day before angiography. Routine laboratory 
analyses, BNP, NT-proBNP and adiponectin were measured immediately 
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before renal angiography in all patients. In patients that were subjected to 
PTRA, analyses were repeated 4 weeks after intervention (except for 
adiponectin). Office BP was measured immediately before, 1 day after and 4 
weeks after renal angiography. Ambulatory (24h) BP (ABP) was measured 
one day before angiography and 4 weeks after PTRA. The same healthy 
control group as in study II (n=20) was studied at one time-point and data 
were compared with baseline values from hypertensive patients.  
3.1.4 Patients and protocol paper IV 
All randomized patients from the Sahlgrenska University Hospital (n=48) 
were included in this study (24 patients in each group). Measurements were 
carried out at randomization and after 11 and 35 months. Analyses included 
office BP, ABP, inflammatory biomarkers, estimated glomerular filtration 
rate (eGFR) and renography for assessment of split kidney function. Thirty-
eight patients completed the study (19 patients from each group). The study 
flow chart is shown in figure 5.  
 
 
Figure 5. Study flow chart. Patients from  Sahlgrenska University Hospital. Eligible 
individuals were patients with a clinical suspicion of atherosclerotic renal artery 
stenosis (RAS) together with a positive diagnostic screening test. Abbreviations are: 
PTRA, percutaneous transluminal renal angioplasty; ARVD, atherosclerotic 
renovascular disease; ARVD-C, control group; ARVD-CAN, candesartan group.  
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3.1.5 Ethical statement 
The Ethics Committee of the University of Gothenburg and Lund approved 
the study and all participants gave their written consent to participate. 
3.2 Measurements 
Systolic (SBP) and diastolic (DBP) office BP were measured in the non-
dominant arm, in a sitting position after 5 minutes rest in the morning before 
drug intake. Ambulatory SBP (ASBP) and DBP (ADBP) were measured for 
24 h by an ambulatory BP device (Model 90217, Spacelabs Healthcare). ABP 
was measured every twenty minutes between 6 am and 10 pm and every sixty 
minutes between 10 pm and 6 am. Estimated GFR was calculated  based on 
serum creatinine concentrations according to the 4-variable equation from the 
Modification of Diet in Renal Disease Study (MDRD) [107].  
3.3 Biochemical analyses 
3.3.1 Routine laboratory methods 
Standard laboratory methods at the Departments of Clinical Chemistry at the 
Sahlgrenska University Hospital and the Malmö University Hospital 
(SWEDAC approved according to European norm 45001) were used for 
routine analyses. Plasma renin activity (PRA) was measured by a 
radioimmunoassay (RIA) kit (Dia Sorin, Stillwater, MN, USA), with inter- 
and intra-assay coefficients of variation (CV)s less than 10%. Plasma 
concentrations of Ang II (Euro-Diagnostica, Malmö, Sweden) were also 
measured by RIA.  
3.3.2 Inflammatory biomarkers and endothelin-1 
Serum high-sensitivity C-reactive protein (hs-CRP) was analysed by rate 
turbidimetry at the Department of Clinical Chemistry at Malmö University 
Hospital. The detection limit was 0.2 mg/l, and the inter assay coefficients of 
variation were 6% at 15 mg/l and 5% at 85 mg/l. All other inflammatory 
biomarkers and ET-1 were analysed at the Wallenberg Laboratory, Malmö 
University Hospital. ET-1 (Nichols Institute Diagnostics, San Juan 
Capistrano, CA, USA) was measured by RIA kits. The detection limit for 
ET-1 was 0.25 pg/ml, the intra-assay CV based on pooled samples was 
11.3%, and the inter-assay CV was 22%. Plasma TNFα and IL-6 were 
measured by enzyme-linked immunosorbent assay (ELISA) using 
commercially available kits (Pharmingen, San Diego, California, USA). 
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Detection limits were 0.12 and 0.70 pg/ml respectively and the intra- and 
inter assay CV were 8.8 and 16.7% for TNFα and 4.2 and 6.4% for IL-6.  P-
neopterin was determined by ELISA (Henning, Berlin, Germany). The 
detection limit was 2 nmol/l, and the intra- and inter-assay CV were 1.7 and 
8.2%, respectively. P-CD40L was analysed by an immunoassay using a 
commercially available kit (R&D Systems Inc, Minneapolis, USA). The 
detection limit was 2.1 pg/ml.  
3.3.3 Lipoproteins  
Venous blood for analyses of lipids, lipoproteins and apolipoproteins was 
collected into ethylenediaminetetraacetate-containing vacutainer tubes after 
an overnight fast and with individuals in the recumbent position. Plasma 
samples were recovered by low-speed centrifugation for 10 min at 4°C. A 
preservative solution (0.13 % e-aminocaproic acid and 0.1 % thiomerosal) 
was added (10 μl/ml) to all plasma samples and samples were frozen at -70°C 
until shipped on dry ice by air express mail to the Lipid and Lipoprotein 
Laboratory, Oklahoma Medical Research Foundation for analyses. Total 
cholesterol (TC), triglycerides (TG), and HDL-cholesterol (HDL-C) were 
determined by standardized enzymatic procedures as described previously 
[108]. Very-low-density lipoprotein-cholesterol (VLDL-C) was assumed to 
equal one-fifth of the plasma TG concentration, and LDL-cholesterol (LDL-
C) levels were calculated by the procedure of Friedewald et al [109]. 
Measurements of ApoA-I, ApoB, ApoC-III, and ApoE and the quantification 
of ApoC-III bound to ApoA-containing (HDL) and ApoB-containing (VLDL 
+LDL) lipoproteins, performed on heparin Mn2+ supernates (ApoC-III 
heparin manganese supernate) and heparin Mn2+ precipitates (ApoC-III 
heparin manganese precipitate), were carried out as described previously [82, 
108]. 
Plasma concentrations of LpA-I and LpA-I:A-II subclasses of high-density 
properties were determined by a differential electroimmunoassay [110]. 
Determination of plasma levels of individual ApoB-containing lipoprotein 
subclasses, LpB, LpB:C, LpB:C:E, and LpAII:B:C:D:E, was performed by 
sequential immunoaffinity chromatography of ApoB-containing lipoproteins 
as previously described [111]. Methods for analyses of plasma lipids, 
apolipoproteins and lipoprotein subclasses have been described elsewhere in 
detail [82, 111, 112] . 
3.3.4 BNP, NT-proBNP and adiponectin 
Brain natriuretic peptide was analysed using the manual Shionoria BNP 
method (CIS Bio international, Gif-sur-Yvette, France) on freshly thawed 
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EDTA-plasma samples. The inter-sample CV was between 5.4 and 7.0 %. 
The EDTA-plasma for BNP testing was frozen at -70 C within 2 h after 
collection.  
NT-proBNP was analysed in serum with the Roche Elecsys system on 
Modular E 2551 with a CV between 3.7 and 5.0 %. An ELISA kit from 
LINCO Research Inc. (St. Charles, MO, USA) was used for the 
quantification of plasma adiponectin (CV 8.55%).  
3.4 Renal angiography and angioplasty 
Digital subtraction angiography was used for evaluating renal arteries. A 6 
French (F) vascular sheath was placed percutaneously in the femoral artery 
after 3000-5000 IU of heparin was administered, and the target renal artery 
was selectively engaged with a multipurpose introducer catheter. A 4 French 
catheter was used for measurements of intra-arterial pressure gradients. The 
diameter of stenosis was estimated manually in all cases. Indications for stent 
placement were angioplasty failure (elastic recoil or flow-limiting dissection 
resulting in >30% residual luminal narrowing, absence of antegrade flow, or 
significant residual MAPG), or restenosis. 
3.5 Renography 
Renographic examinations were performed on hydrated patients in the supine 
position using a large field gamma camera (APEX 415, Elscint, Israel). 
Ninety-six frames (64x64 pixels) of 10 seconds each were recorded after an 
intravenous bolus injection of 100 MBq99TCm-DTPA. Time-activity curves 
for the regions of interest over the kidneys were created. Renograms were 
corrected for the extrarenal background signal and normalized for kidney 
area. Relative function was estimated by means of the uptake index as 
previously described [113]. 
3.6 Statistics  
Analyses were performed using one-way analysis of variance (ANOVA). If 
data were not normally distributed, Kruskal-Wallis one-way ANOVA on 
ranks was used. Differences between groups were analyzed with unpaired t-
test or the Mann-Whitney U test and the chi-square test for categorical data. 
Bonferroni corrections were made for multiple comparisons. Paired t-test or 
Wilcoxon signed rank test were used for within group analyses. The Pearson 
correlation (or Spearman correlation when data did not meet assumption 
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about normality) coefficient was used to evaluate correlations. In study II 
multiple linear regression analysis was used to examine the association at 
baseline between apolipoproteins or lipoproteins and demographic, clinical 
and laboratory variables. Variables that were significantly correlated were 
included in multiple regression models. All tests were two-tailed and P-
values <0.05 were considered statistically significant. Data are presented as 
means ± SD. Software SPSS 17.0 (SPSS Inc., Chicago, Illinois, USA) was 
used. 
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4 REVIEW OF RESULTS 
The following is a brief overview of the main results found in each study.  
4.1 Inflammatory biomarkers and ET-1 in 
patients with RAS and effect of renal 
angioplasty during the first month after 
intervention (paper I) 
 
4.1.1 Baseline characteristics and biomarkers prior 
to angiography 
Patients with significant RAS had higher SBP at baseline (p=0.030) and were 
more often men (p=0.024) compared to patients without significant RAS. 
There were no significant differences in inflammatory biomarkers or ET-1 
between the RAS and non-RAS group. However, inflammatory biomarkers 
and ET-1 were significantly elevated in patients with significant RAS 
compared to healthy controls (p<0.001).  
4.1.2 Effect of angioplasty on IL-6 and hs-CRP 
Interleukin-6 (Figure 6) and hs-CRP (Figure 7) had increased both in patients 
with significant RAS and in patients without significant RAS, who   
undergoing angiography only one day after angiography compared to 
baseline. At this time point IL-6 and hs-CRP were significantly elevated in 
the RAS group compared to patients subjected to angiography only.  
One month after PTRA, IL-6 levels had decreased significantly compared to 
before intervention (Figure 6). 
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Figure 6. Effect of angioplasty on Interleukin-6 (IL-6) in patients with significant 
renal artery stenosis (RAS) vs. patients without significant RAS. 
 
 
 
 
 
 
 
 
 
 
Figure 7. Effect of angioplasty in high-sensitivity C-reactive protein (hs-CRP) in 
patients with significant renal artery stenosis (RAS) vs. patients without significant 
RAS. 
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4.1.3 Effect of angioplasty on endotelin-1 
One day after PTRA plasma levels of ET-1 were not significantly different 
compared to before intervention. However, 1 month after PTRA ET-1 levels 
had decreased significantly compared to before intervention (Figure 8). 
 
 
 
 
 
 
 
 
Figure 8. Effect of angioplasty in endothelin-1 (ET-1) in patients with significant 
renal artery stenosis (RAS) vs. patients without significant RAS. 
 
4.2 Lipoproteins abnormalities in patients with 
atherosclerotic renovascular disease 
(paper II)  
4.2.1 Patients characteristics at baseline 
ASBP and ADBP, serum creatinine concentration, leukocyte count, fasting 
plasma glucose concentration, and urinary albumin excretion (UAE) were 
significantly elevated in patients with ARVD compared to controls (p<0.05). 
In addition, eGFR was significantly reduced in ARVD patients compared to 
controls (59±18 vs. 79±14 ml/min/1.73m², p<0.05).  
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4.2.2 Plasma lipids, apolipoproteins and lipoproteins 
at baseline  
Lipids and lipoproteins (Table2) 
 
Table 2. Lipids and lipoproteins at baseline in patients with ARVD treated 
with statins, and in age-matched healthy controls. 
 ARVD (n=42) Controls (n=20) 
TC (mg/dl) 177±36 217±36 
HDL-C (mg/dl) 49±13 65±14 
LDL-C (mg/dl) 96±28 130±38 
VLDL-C (mg/dl) 32±14 23±10 
TG (mg/dl) 166±88 116±49 
                                                                                                                                                    
TC, total cholesterol; HDL-C, high-density lipoprotein-cholesterol; LDL-C, low-density 
lipoprotein-cholesterol; VLDL-C, very low-density lipoprotein-cholesterol; TG, triglycerides. 
Values are means±SD. * denotes p<0.05. 
Apolipoproteins (Table 3) 
 
Table 3. Plasma concentrations of apolipoproteins at baseline in patients 
with ARVD treated with statins, and in age-matched healthy controls 
 
 
 
 
 
 
 
Apo, apolipoprotein; HS, heparin-manganese supernate; HP, heparin-manganese precipitate. 
The ApoC-III ration was calculated as ApoC-III-HS/ApoC-III-HP. Values are means±SD. * 
denotes p<0.05.  
  ARAS   
(n=42) 
Controls  
(n=20) 
ApoA-I (mg/dl) 141±13 141±11 
ApoB (mg/dl) 103±19 95±11 
ApoA-I/ApoB 1.4±0.3 1.5±0.2 
ApoC-III (mg/dl) 12.7±4.6∗ 8.8±2.6 
ApoC-III-HS (mg/dl) 8.9±3.2∗ 5.3±1.8 
ApoC-III-HP (mg/dl) 3.9±1.8∗ 3.0±1.2 
ApoC-III-ratio 2.5±0.9 2.4±1.6 
ApoA-I/ApoC-III  12.1±3.5* 17.2±4.6 
ApoE (mg/dl) 8.2±2.3* 6.7±1.1 
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Lipoprotein subclasses (Table 4) 
 
Table 4. Lipoprotein subclasses at baseline in patients with ARVD treated 
with statins, and in age-matched healthy controls. 
 
ApoC-III-containing Lp:s were calculated as LpB:C + LpB:C:E + LpA-II:B:C:D:E. Values are 
means±SD. * denotes p<0.05. 
4.2.3 Multiple regression analysis  
As the most striking findings in this study were increase in ApoC-III, and 
ApoC-III-containing lipoproteins in patients with ARVD, we analysed which 
variables that were significantly correlated with ApoC-III. Only ASBP, 
ADBP, and PRA were significantly correlated to ApoC-III and these 
variables were included in a multiple regression analysis as predictors. In this 
model only PRA was significantly associated with ApoC-III (p<0.001, 
r=0.74, figure 9). Notably, ApoC-III was not correlated to age, BMI, fasting 
plasma glucose, serum creatinine, eGFR, UAE, leukocyte count or serum 
albumin levels. 
 
 
 ARVD  (n=42) Controls (n=20) 
LpA-I, mg/dl 
LpA-I:A-II, mg/dl 
LpB, mg/dl 
LpB:C, mg/dl 
LpB:C:E, mg/dl 
LpA-II:B:C:D:E, mg/dl 
ApoC-III-containing Lp:s, mg/dl 
35±4 
107±10 
57.0±7.8 
11.1±4.1 
13.3±5.4* 
21.4±8.9 
46±15* 
33±2 
108±9 
57.7±4.5 
9.5±4.1 
8.4±4.3 
19.2±7.0 
37±8 
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Figure 9. Correlation between PRA and ApoC-III in patients with ARVD (n=42) at 
baseline 4 weeks after PTRA. In a multiple regression model, only PRA was 
significantly associated with ApoC-III (p<0.001, r=0.74). Abbreviations are: ApoC-
III, apolipoprotein C-III; PRA, plasma renin activity; ARVD, atherosclerotic 
renovascular disease; PTRA, percutaneous transluminal renal angioplasty.  
4.2.4 Effects of candesartan on lipoproteins in ARVD 
patients 
Analyses 11 months after randomization showed that candesartan treatment 
had no statistically significant effects on lipoproteins levels.  
 
 
4.3 Brain natriuretic peptides in atherosclerotic 
renal artery stenosis and effects of renal 
angioplasty (paper III) 
4.3.1 BNP, NT-proBNP and adiponectin at baseline  
Plasma BNP and NT-proBNP concentrations were elevated in patients with 
significant ARAS compared to healthy controls (82±99 vs. 28±20, p<0.05 for 
BNP and 521±737 vs. 87±55, p<0.05 for NT-proBNP), but not in comparison 
to hypertensive individuals without RAS (82±99 vs. 48±68 for BNP and 
521±737 vs. 350±808 for NT-proBNP). Plasma adiponectin was significantly 
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reduced in the ARAS group compared to controls (9.3±7.5 vs.12.0±4.9, 
p<0.05), however, this difference did not reach statistical significance when 
patients with diabetes had been excluded from the analysis.   
Correlation analyses at baseline  
In patients with ARAS, baseline BNP and NT-proBNP levels were correlated 
significantly to age, ASBP, ambulatory PP, serum creatinine, eGFR and UAE 
(Table 5). However, in multiple regression analysis only serum creatinine 
levels showed a statistically significant relationship to both BNP and NT-
proBNP (r=0.42, p<0.05 for BNP; and r=0.67, p<0.001 for NT-proBNP). 
Table 5.Correlation between BNP, NT-proBNP, adiponectin and other 
variables at baseline in patients with significant atherosclerotic renal artery 
stenosis.    
 S-BNP S-NT-proBNP P-Adiponectin 
Age, years r=0.506** r=0.522** ns 
BMI, kg/m² ns ns r=-0.340* 
ASBP, mmHg r=0.374** r=0.520* ns 
ADBP, mmHg ns ns r=0.308* 
Ambulatory PP, mmHg r=0.515** r=0.640** ns 
S-creatinine, μmol/L r=0.428** r=0.476** ns 
eGFR, ml/min/1.73m² r= –0.547** r= –0.644 ** ns 
UAE, mg/day r=0.327* r=0.365* ns 
S-HDL-C, mmol/L ns ns r=0.538* 
                                                                                                                                       
Statistically significant correlation coefficients are presented. BNP, brain natriuretic peptide;  
NT-proBNP, N-terminal pro-B-type natriuretic peptide; BMI, body mass index;  ASBP, 
ambulatory systolic blood pressure; ADBP, ambulatory diastolic blood pressure; PP, pulse 
pressure; eGFR, estimated glomerular filtration rate according to the 4-variable equation from 
the Modification of Diet in Renal Disease  Study (MDRD); UAE, total 24-h urinary albumin 
excretion; S-HDL-C, serum high-density lipoprotein-cholesterol.* p<0.05; ** p<0.01. 
Plasma adiponectin levels showed a significant correlation to BMI, ADBP 
and S-HDL-C (Table 5, figure 10B), but in multiple regression analysis only 
S-HDL-C showed a significant correlation. Notably, there was a statistically 
significant, and similar, correlation between plasma adiponectin and S-HDL-
C also in the non-RAS group (Figure 10A). 
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Figure 10. Relationship between 
plasma adiponectin concentration 
and serum levels of high-density 
lipoprotein (HDL) cholesterol in 
patients undergoing renal 
angiography because of suspected 
atherosclerotic renal artery 
stenosis (RAS). Out of these, 41 
patients had no significant RAS 
(A) and 43 patients had 
atherosclerotic renal artery 
stenosis (ARAS)(B). There was a 
statistically significant correlation 
between plasma adiponectin levels 
and S-HDL cholesterol in both 
groups (p<0.01). 
 
4.3.2 Effects of PTRA on blood pressure, kidney 
function and biomarkers  
ASBP, ADBP and ambulatory PP had decreased significantly 4 weeks after 
PTRA (p<0.01) (Figure 11). Serum creatinine levels and eGFR were not 
significantly affected by PTRA (Figure 11).  
 
Figure11.  Ambulatory systolic (SBP) and diastolic (DBP) blood pressure and serum 
creatinine levels before (pre-PTRA) and 4 weeks after (post-PTRA) percutaneous 
transluminal renal angioplasty (PTRA) in patients with atherosclerotic renal artery 
stenosis. Values are means ±SD. **denotes p<0.01 versus baseline. 
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Effects of PTRA on BNP and NT-proBNP 
PTRA had no statistically significant effects on serum BNP or NT-proBNP 
when analyzed 4 weeks after intervention (Figure 12). 
 
 
 
 
 
Figure 12. Serum concentration of brain natriuretic peptide (BNP) and N-terminal pro-
BNP (NT-pro BNP) before (pre-PTRA) and 4 weeks after (post-PTRA) percutaneous 
transluminal renal angioplasty (PTRA) in patients with atherosclerotic renal artery 
stenosis. Values are means ±SD. There were no statistically significant effects of PTRA.  
4.3.3 Correlation of baseline data to changes in 
ASBP and BNP in response to PTRA 
Changes in ASBP in response to PTRA were significantly correlated to 
baseline ASBP, ambulatory PP, eGFR, plasma glucose, and plasma Ang II. 
However, in a stepwise multiple regression analysis, only baseline ASBP, 
plasma glucose and Ang II significantly predicted changes in ASBP.  
There was no threshold plasma BNP concentration above which PTRA was 
shown to cause a more pronounced BP reduction. There was no significant 
difference in BP response to PTRA between patients from the highest and the 
lowest quartiles of baseline BNP values. However, there were statistically 
significant correlations between changes in ASBP and delta BNP (Figure 13) 
and delta NT-proBNP in response to PTRA.  
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Figure 13. Correlation between change in ambulatory systolic blood pressure (SBP)    
and change in serum brain natriuretic peptide (BNP) concentration in response to  
percutaneous transluminal renal angioplasty (r=0.57, p<0.001) in patients with  
atherosclerotic renal artery stenosis. 
 
4.4 Effects of candesartan on kidney function 
and inflammatory biomarkers in 
hypertensive patients subjected to renal 
angioplasty of atherosclerotic renal artery 
stenosis (paper IV) 
4.4.1 Patient follow-up  
Of the 48 patients randomized 38 patients (19 patients from each group) 
completed the study. In group ARVD-CAN 4 patients died (2 from malignant 
disease, 1 from head injury and 1 from a PTRA-related complication) and 1 
patient did not want to participate further. In group ARVD-C 1 patient died 
(from pulmonary embolism) and 4 discontinued for other reasons (2 
violations of study protocol, 1 had a major stroke and could not cooperate, 1 
needed dialysis).  
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4.4.2 Effects of candesartan on blood pressure and 
kidney function  
Ambulatory SBP and ADBP decreased significantly in both groups following 
randomization. However, the relative reduction in ASBP was significantly 
greater in group ARVD-CAN vs. ARVD-C (p<0.05). There was no 
difference between groups in ASBP or ADBP at 35 months after 
randomization (Table 6).  
Table 6. Blood pressure and kidney function in patients with atherosclerotic 
renovascular disease (ARVD) at baseline and 35 months after randomization. 
  ARVD-C  (n=19) ARVD-CAN (n=19) 
baseline  35 
months 
% change baseline 35 months % change 
Office SBP, mmHg 150±22 148±14 0.1±14.0 159±21 146±17* -7.1±12.0 
Office DBP, mmHg 84±11 83±9 -0.6±14.6 88±11 85±15 -3.4±14.1 
ASBP, mmHg 132±12 126±10* -4.4±8.4 144±14 128±13* -12.2±9.7† 
ADBP, mmHg 75±8 70±8* -5.7±8.3 79±12 74±11* -6.9±8.5 
S-creatinine, µmol/L 101±24 100±31 -1.3±15.3 115±46 113±35 2.6±21.9 
eGFR, ml/min/1.73m² 62±15 63±17 0.8±18.6 58±21 57±21 1.8±27.3 
UAE mg/day 103±224 287±649 240±950 117±157 49±72 3±113 
 
Abbreviations are: ARVD-C, control group; ARVD-CAN, candesartan group; SBP, systolic 
blood pressure; DBP, diastolic blood pressure ; ASBP, ambulatory systolic blood pressure; 
ADBP, ambulatory diastolic blood pressure; eGFR, estimated glomerular filtration rate 
according to the 4-variable equation from the Modification of Diet in Renal Disease  Study 
(MDRD); UAE, urinary albumin excretion. Values are means±SD. *denotes p<0.05 within 
group effect 35 months after randomization vs. baseline; and † denotes p<0.05 ARVD-CAN 
vs. ARVD-C. 
 
Total eGFR, eGFR of the revascularized kidney, and urinary albumin 
excretion, did not change significantly during 35 months follow-up in any of 
the groups and there were no significant between group differences (Figure 
14). 
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Figure 14. Estimated glomerular filtration  rate in patients with atherosclerotic 
renovascular disease. Estimated glomerular filtration rate (eGFR) was determined at the 
time of randomization, and 11 and 35 months thereafter. Presented values are for both 
kidneys and for the previously stenotic kidney that had been subjected to 
revascularization four weeks prior to randomization. Estimated glomerular filtration rate 
according to the 4-variable equation from the Modification of Diet in Renal Disease 
Study (MDRD); Single kidney eGFR was calculated from split-kidney function data 
derived from DPTA renography. Values are means±SD. Abbreviations are: ARVD, 
atherosclerotic renovascular disease; ARVD-C, control group; ARVD-CAN, candesartan 
group. 
 
4.4.3 Effects of candesartan on inflammatory 
biomarkers, PRA, Ang II and ET-1 
There was no statistically significant difference between candesartan, and 
control treatment, on plasma levels of inflammatory biomarkers or 
endothelin-1.  Plasma renin activity increased significantly in the ARVD-
CAN group vs. ARVD-C (Table 7). 
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Table 7. Plasma biomarkers in patients with atherosclerotic renovascular 
disease (ARVD) at baseline and 35 months after randomization. 
  ARVD-C  (n=19) ARVD-CAN (n=19) 
baseline  35 months % change baseline 35 months % change 
Leukocytes, 109/L 7.2±2.1 7.2±1.5 2.6±18.3 7.9±2.1 7.7±1.4 0.3±14.9 
hs-CRP, mg/dl 3.5±2.7 2.3±1.0 1.5±61.4 5.5±6.6 7.0±10.7 39.4±81.6 
IL-6, pg/ml 4.0±8.5 2.7±1.9 161±308 3.6±3.0 3.5±2.9 95±254 
TNFα, pg/ml 1.4±0.9 1.3±0.8 16.7±79.9 1.5±0.5 1.7±0.8 23.4±72.6 
Uric acid, µmol/L 342±64 357±81 6.2±24.9 377±105 390±99 8.6±19.7 
ET-1, pg/ml 1.0±0.4 1.1±0.4 24.0±74.4 1.1±0.4 1.2±0.6 15.0±62.2 
PRA, ngAngI/ml/h 1.3±1.5 1.2±1.0 36±133 2.1±2.6 10.6±18.8* 1463±3113† 
Ang II, pg/ml 9.7±4.2 17.2±10.5* 121±200 13.2±7.6 34.0±39.1* 176±248 
                                                                                                                                   
Abbreviations are: ARVD-C, control group; ARVD-CAN, candesartan group; hs-CRP, high-
sensitivity C-reactive protein; IL-6, interleukin 6; TNFα, tumor necrosis factor-α; PRA, plasma 
renin activity; Ang II, plasma angiotensin II;  ET-1, endothelin 1. Values are means±SD. 
*denotes p<0.05 within group effect and † denotes p<0.05 ARVD-CAN vs. ARVD-C. 
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5 DISCUSSION 
Inflammation and endothelin-1 in patients with renal artery 
stenosis and effects of renal angioplasty and candesartan  
In our first study we investigated inflammatory biomarkers and ET-1 in 
patients with RAS and evaluated how treatment with PTRA affected these 
variables during the first month after intervention. We found that all patients 
with suspected RAS had increased levels of inflammatory biomarkers 
compared to healthy controls, with the exception of CD40L. As previously 
reported for IL-6 and CRP [114], we found no differences in inflammatory 
activity between patients with hemodynamically significant RAS and those 
without significant RAS. These data suggest that the increase in 
inflammatory activity is related to generalized atherosclerosis and not to the 
renal artery stenosis per se. Moreover, we observed that leukocyte count, hs-
CRP, and IL-6 increased transiently after renal angiography, irrespective of 
whether PTRA with or without stenting was performed. This inflammatory 
reaction was, however, significantly more pronounced in patient subjected to 
PTRA compared to those undergoing only angiography. Previously, studies 
have shown that renal artery stent placement triggers an inflammatory 
response with increased CRP and IL-6 levels during the first 24 hours after 
PTRA [114], and we extend those findings in a larger patient group. It must 
be kept in mind that all our patients were on antiplatelet therapy (ASA or 
clopidogrel) and statin treatment, which may have attenuated the 
inflammatory response. Statins are known to inhibit increases in IL-6 and hs-
CRP after percutaneous coronary intervention [115]. Interestingly, in our 
study IL-6 had decreased compared to baseline one month after PTRA, 
suggesting beneficial effects of PTRA upon inflammatory activity in patients 
with RAS [69].  
The impact of PTRA on other inflammatory biomarkers was varied. TNFα 
levels decreased significantly on the day after PTRA. TNFα responses have 
been investigated previously after femoral percutaneous transluminal 
angioplasty [116, 117]. A prompt increase followed by an exhaustion of 
TNFα levels 4 h after the intervention was shown. Such a transient increase 
cannot be excluded in our patients, as we did not collect blood samples until 
the day after intervention.   
The levels of another inflammatory biomarker, such as CD40L, were lower at 
baseline in patients with RAS compared to the healthy controls. This 
surprising finding might be explained by the fact that all patients were on 
statins, which in some [118], but not all [115] studies has been shown to 
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weaken CD40L responses. CD40L levels are related to platelet activation 
[75, 115, 118, 119], and have been reported to reach a peak after one month 
in patients undergoing percutaneous coronary intervention [120]. Our results 
are compatible with this finding since we demonstrated elevated CD40L 
levels one month after intervention. This might have been due to late platelet 
and inflammatory responses caused by mechanical vessel dilatation and, in 
some patients, stent placement.  
There is still controversy regarding ET-1 in renovascular hypertension. In 
several earlier studies [121-123] it has been shown that circulating ET-1 does 
not differ significantly between patients with renovascular and primary 
hypertension, even though the activity of the renin-angiotensin system is 
clearly increased in RVH [115]. Other studies [124] have reported increased 
ET-1 levels in patients with RAS. In our study only patients with significant 
RAS, who then underwent PTRA had increased plasma ET-1 levels at 
baseline (i.e. before angioplasty) compared to healthy controls. ET-1 levels 
did not change one day after angiography/angioplasty. However, one month 
after PTRA levels of ET-1 had decreased significantly in the group with 
significant RAS compared to before intervention, suggesting a beneficial 
effect of PTRA on the endothelin system. The fact that ET-1 levels were no 
longer elevated compared to healthy controls one month after intervention 
suggests that a hemodynamically significant RAS is associated with 
increased ET-1 levels [124], which may be lowered by endovascular 
correction of the stenosis.  
In study 4 we investigated inflammatory biomarkers and ET-1 in patients 
with ARVD and residual hypertension after revascularization of renal artery 
stenosis. The aim of this study was to examine long-term effects of 
angiotensin II receptor antagonism, with candesartan, on inflammation and 
ET-1.  
Hypertension and atherosclerosis are disorders associated with inflammation 
and studies have demonstrated that ARBs exert anti-inflammatory effects 
[125]. Several mechanisms have been proposed for these beneficial actions of 
ARBs, such as reduced production of mitochondrial reactive oxygen species 
[126] and cytokines [127], and via activation of the peroxisome proliferation-
activated receptor-gamma [128]. In the present study candesartan did not 
affect inflammatory biomarkers and ET-1 during 35 months follow up and 
hence did not support a specific anti-inflammatory effect of ARBs in this 
cohort of ARVD patients. All patients in the present study were taking 
statins, a class of drugs known to have anti-inflammatory actions. It is 
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possible that the use of statins made it more difficult to detect anti-
inflammatory effects of candesartan. 
In conclusion, we found that patients with significant RAS had increased 
levels of inflammatory biomarkers and ET-1 compared to healthy subjects. 
PTRA triggers a rapid, transient, increase in hs-CRP and IL-6. However, one 
month after PTRA, both IL-6 and ET-1 had decreased compared to before 
intervention, indicating beneficial effects of PTRA on inflammation and the 
endothelin system. However, candesartan did not show beneficial effects on 
inflammatory biomarkers or the endothelin system during 35 months of 
follow up.  
Lipoprotein abnormalities in patients with atherosclerotic 
renovascular disease and effects on candesartan 
In study 2 we examined lipoprotein abnormalities in patients with ARVD 
who had undergone PTRA and analyzed whether angiotensin II receptor 
antagonism influenced these abnormalities. We found that patients with 
ARVD who underwent PTRA four weeks earlier had increased plasma 
concentrations of TG, VLDL-C, ApoC-III and ApoC-containing lipoproteins 
compared to healthy controls in spite of ongoing treatment with statins. These 
lipoproteins were elevated even though concentration of TC and LDL-C were 
significantly reduced in this group most likely as a consequence of ongoing 
treatment with statins.  
The ApoC-III-containing lipoproteins that in addition to ApoB also contain 
ApoC-III have triglycerides as the major lipid constituent and are generally 
referred to as triglyceride-rich. The lipoprotein abnormalities in ARVD 
patients show clear similarities to the renal dyslipidemia described in patients 
with CKD and reduced GFR. It is characterized by increased levels of 
triglyceride-rich ApoB- and ApoC-containing lipoproteins that typically 
express ApoC-III [80, 81]. However, ARVD patients showed an increase 
mainly in LpB:C:E in contrast to CKD patients in which specifically LpB:C 
particles are highly increased [111]. Abnormalities in the spectrum and 
composition of individual lipoprotein particles in renal dyslipidemia are 
present in both normolipidemic and hyperlipidemic CKD patients and can be 
detected already when kidney function is moderately reduced [89, 129]. In 
study 2, patients had an average eGFR of 59 ml/min/1.73 m², and it is 
possible that the reduction in GFR, per se, could have contributed to 
dyslipidemia. However, using multiple regression analysis we could not 
detect a significant association between eGFR and ApoC-III levels in ARVD 
patients, suggesting that other mechanisms were involved.  
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It should be noted that all ARVD patients were on statin treatment in the 
present study and that this could have masked underlying lipoprotein 
abnormalities. In previous studies it has been  shown that statin treatment 
effectively reduces cholesterol-rich ApoB-containing lipoproteins including 
their characteristic lipid and apolipoprotein constituents (TC, LDL-C, ApoB, 
and ApoE) in CKD patients [108, 111] as well as in other patient groups 
[130, 131]. However, statins are much less effective in reducing triglyceride-
rich ApoB- and ApoC-containing lipoproteins such as LpB:C and LpB:C:E 
and their constituents VLDL-C, TG, and ApoC-III [108, 111]. Although the 
present study was not designed to examine the effects of statins on 
lipoprotein abnormalities, our results are in agreement with earlier findings in 
other patient groups and suggest that statin treatment does not normalize 
triglyceride-rich ApoB- and ApoC-containing lipoproteins in ARVD patients. 
Taking into consideration that cardiovascular disease is the major cause of 
death in patients with ARVD [44] it is intriguing that lipoprotein 
abnormalities in ARVD patients on statin treatment in the present study have 
previously been shown to be atherogenic [132-135]. In the Monitored 
Atherosclerosis Regression Study (MARS), elevated levels of ApoB- and 
ApoC-containing triglyceride-rich lipoproteins, and ApoC-III, contributed 
significantly to the progression of coronary artery disease as evaluated by 
sequential coronary angiography [132]. In addition, in the Cholesterol and 
Recurrent Events (CARE) trial increased ApoC-III concentration in VLDL 
and IDL (intermediate-density lipoprotein-cholesterol) was a strong predictor 
of coronary events [134]. Furthermore, recent analyses from the Hoorn study 
showed that an increased plasma ApoC-III concentration independently was 
associated with cardiovascular mortality [135]. In the current study, both total 
ApoC-III and ApoC-III-HP (i.e. ApoC-III in triglyceride-rich VLDL+LDL) 
were elevated in ARVD patients and these alterations may play a 
pathophysiological role both in the development of dyslipidemia and in the 
vascular disease process in these individuals. ApoC-III is a major regulator of 
lipolysis primarily by inhibiting endothelial-bound lipoprotein lipase (LPL), 
the principal enzyme necessary for the hydrolysis of triglyceride-rich 
lipoproteins [136]. Thus, the finding of increased ApoC-III levels in the 
present study may reflect the accumulation of intact and partially metabolized 
ApoB- and ApoC-containing lipoproteins due to a retarded catabolism of 
these lipoproteins. In addition, increased ApoC-III per se may promote the 
development of atherosclerosis by stimulating the activation and adhesion of 
peripheral monocytes to endothelial cells [137, 138].  
A potentially effective therapy in patients with ARVD would be the 
combination of statins with fibrates, although other therapies could also be 
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considered. Fibrates and other peroxisome proliferator-activated receptor 
(PPAR) agonists have the potential to beneficially affect the catabolism of 
triglyceride-rich ApoB- and ApoC-containing lipoproteins [139]. Although 
PPAR agonists have the potential to correct dyslipidemia in ARVD, this 
hypothesis, and the impact on clinical endpoints need to be tested in clinical 
trials.  
In the present study there was a significant association between PRA and 
ApoC-III levels in ARVD patients suggesting that an activation of the renin-
angiotensin system could increase ApoC-III. Still, treatment with candesartan 
for 11 months did not significantly influence plasma levels of ApoC-III or 
ApoC-containing lipoproteins, indicating that Ang II, via the Ang II type-1 
receptor, was not causatively involved. However, the number of patients in 
the present study was small and larger studies are warranted.  
In conclusion, we found that patients with ARVD had elevated levels of 
triglyceride-rich ApoC-III-containing lipoproteins and increased ApoC-III in 
spite of ongoing treatment with statins. These lipoprotein abnormalities, 
which were not corrected by candesartan treatment, have previously been 
shown to be atherogenic and may contribute to progressive atherosclerosis in 
ARVD patients.  
Brain natriuretic peptides in atherosclerotic renal artery 
stenosis and effects of renal angioplasty 
In study 3 we found that hypertensive patients with ARAS had significantly 
elevated plasma concentrations of BNP and NT-proBNP compared to healthy 
controls, but not in comparison to hypertensive patients without RAS. This 
observation clearly suggests that other causes than RAS per se were 
responsible for the increased BNP levels in ARAS patients. In fact, multiple 
regression analysis showed that serum creatinine was the only variable that 
was significantly correlated to both plasma BNP and NT-proBNP levels in 
ARAS patients. Hence, differences in kidney function likely explained the 
increase in BNP and NT-proBNP in ARAS subjects vs. healthy controls since 
patients with ARAS had reduced GFR. On the contrary, serum creatinine 
levels were similar in hypertensive patients with or without RAS.  
The other main finding in this study was that plasma BNP and NT-proBNP 
could not be used to predict the outcome of PTRA on blood pressure and we 
could not identify a pre-interventional plasma BNP or NT-proBNP level 
above which a successful revascularization could be expected. We have 
observed that although PTRA did not significantly affect BNP or NT-
proBNP concentrations in patients with ARAS, there were a significant 
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correlation between changes in plasma BNPs and changes in blood pressure 
in response to intervention. The mechanisms underlying this correlation 
remain speculative but could theoretically be explained by reduced left 
ventricular afterload secondary to the fall in blood pressure, decreased 
activity of RAAS, or restoration of pressure-natriuresis in the previously 
stenotic kidney.  
Our data do not confirm the results of two previous studies in which baseline 
BNP levels were shown to predict the blood pressure response after 
revascularization in patients with RAS [140, 141]. There are a number of 
possible explanations for the discrepant results in our study compared to 
those previously published. First, in both the earlier studies [140, 141] 
patients with bilateral RAS were included whereas we only investigated 
patients with unilateral RAS. In the study by Silva et al [140] the proportion 
of patients with bilateral RAS was as high as 33%. It is possible to speculate 
that patients with bilateral RAS, who in general have a more volume-
dependent hypertension, would have increased plasma levels of BNP at 
baseline and respond to revascularization with a more pronounced BNP 
reduction. Secondly, Staub et al [141] included patients with FMD, who 
made up 22% of all patients with a successful blood pressure response, while 
only patients with ARAS participated in study 3. Thirdly, the majority of 
patients included in the two previous studies were on treatment with ACEI or 
ARBs whereas none of the patients in our study were on medications that 
inhibited the RAAS. It is well known that cardiac BNP synthesis and release 
is stimulated by both hemodynamic mechanisms and by direct, non-
hemodynamic, pathways via neuroendocrine factors such as Ang II [98, 99]. 
In our study, revascularization had no significant effects on either plasma 
Ang II levels or PRA and it is therefore possible that Ang II driven BNP 
production prevented reductions in plasma BNP levels following 
intervention.  
Chrysochou et al [142] examined the prognostic role of NT-proBNP in 
patients with ARAS and found that elevated NT-proBNP levels were 
associated with a greater likelihood of death when subdivided by CKD stage. 
Thus, although these authors showed that kidney function was a more 
important risk factor for CV events and death, there was an additive risk 
effect of NT-proBNP. Therefore, according to these authors, measurements 
of BNPs might be helpful in identifying ARAS patients with increased CV 
risk and in need of intensified management.  
Another interesting finding in our study was reduced adiponectin in patients 
with ARAS compared to healthy controls. We observed a significant 
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correlation between low plasma adiponectin levels and low S-HDL-C 
concentrations in both hypertensive groups (ARAS and non-RAS), which is 
compatible with previous findings in patients with the metabolic syndrome 
and type 2 diabetes [143]. It has previously been shown that low adiponectin 
levels predict elevated plasma VLDL-ApoB concentrations through impaired 
catabolism of triglyceride rich lipoproteins [144]. Hence, it is possible that 
suppressed adiponectin levels in ARAS patients may contribute to the 
dyslipidemia described in study 2.  
In conclusion, we found that hypertensive patients with ARAS have elevated 
plasma concentrations of BNP and NT-proBNP, but reduced adiponectin 
levels, compared to healthy controls. However, concentrations of these 
biomarkers were not significantly different in ARAS patients compared to 
hypertensive subjects without RAS. The increases in plasma BNP and NT-
proBNP vs. healthy controls were most likely explained by reduced kidney 
function in ARAS patients. In addition, baseline levels of BNPs could not be 
used to predict the outcome of PTRA on blood pressure.  
Effects of candesartan on kidney function in hypertensive 
patients subjected to renal angioplasty of atherosclerotic renal 
artery stenosis 
In study 4 we examined long-term effects of candesartan on kidney function 
in patients with ARVD and residual hypertension after revascularization of 
renal artery. We found that candesartan treatment during three years had no 
statistically significant effects on kidney function compared to 
antihypertensive treatment without RAAS inhibitors. 
Several studies have provided evidence that renin-angiotensin system 
blockade with ACEIs or ARBs has specific renoprotective effects and are the 
drugs of choice for treatment of hypertension in patients with CKD and 
albuminuria [145]. In our study, the level of albuminuria increased more than 
2-fold in the control group during follow-up whereas albuminuria levels 
decreased in candesartan-treated patients. Although this difference between 
groups did not reach statistical significance, it suggested a renoprotective 
effect of ARBs also in this category of patients. Interestingly, the rate of 
urinary albumin excretion 35 months after randomization was numerically 
lower in group ARVD-CAN, compared to controls, in spite of ambulatory 
BPs being somewhat higher in the ARVD-CAN group. This suggests that the 
effect of candesartan on albuminuria was caused by an intrarenal mechanism 
independent of systemic hemodynamics. The pathophysiological explanation 
of this observation could be that the intrarenal RAAS remains activated 
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following revascularization due to the existence of significant stenosis in 
smaller arteries located more distally. 
Pharmacological blockade of the RAAS in hypertensive patients with ARAS 
was initially considered contraindicated due to fear of inducing renal 
ischemia, hence accelerating renal fibrosis and progression towards end stage 
renal disease (ESRD) [33, 34]. However, in several studies BP control was 
demonstrated to be remarkably improved by the use of ACEI [37]. Losito et 
al [37] evaluated cardiovascular and renal survival in a long term follow-up 
study of 195 patients with renal artery stenosis, of which 135 patients 
underwent revascularization. Multivariate analysis disclosed that 
revascularization was not associated with reduced mortality or improved 
renal survival when compared to medical treatment. However, the use of 
ACEI was associated with longer survival (p=0.002) in both revascularized 
and medically treated patients [37], indicating that RAAS-blockade is 
important in the management of ARVD patients.  
In our study, total eGFR, and eGFR of the previously revascularized kidney, 
did not change significantly during 35 months follow-up in any of the groups 
and there was no significance between group differences. Hence, candesartan 
did not impair renal function during 35 months of follow up after 
revascularization and no patient developed acute kidney injury. It is feasible 
to speculate that RAAS-blockade may attenuate disease progression in 
ARVD patients although this was not observed in the present study. 
Obviously, a much larger study with a longer follow up would be needed to 
address this issue appropriately.  
The obvious limitation of this study was the small number of patients. A 
main reason for this was the stringent inclusion criteria. In addition, the 
number of patients with ARAS undergoing PTRA has decreased dramatically 
during the last 10-years due to the negative results from randomized clinical 
trials that were published during the period when patients were recruited to 
the present study [31, 32]. 
In conclusion, in patients with ARVD who had undergone revascularization 
of renal artery stenosis, candesartan-based antihypertensive therapy did not 
show any significant effects on kidney function compared to control 
treatment. However, candesartan-based therapy was well tolerated and 
without renal side-effects.   
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6 CONLUSIONS AND FUTURE 
PERSPECTIVES 
What did we know before our study and what do we know now? 
Before we started our study we knew that patients with RVH caused by 
atherosclerotic RAS had a much worse prognosis than patients with primary 
hypertension. In addition, we knew that this difference in prognosis was 
explained by an elevated cardiovascular risk [43, 44]. However, the reason 
for the increase in cardiovascular events was not clearly understood. We also 
did not know how to treat these patients ideally to reduce cardiovascular risk 
and to improve survival.  
We speculated that non-traditional cardiovascular risk factors may contribute 
to the high cardiovascular morbidity and mortality in this patient group. We 
investigated these factors and examined whether treatment with PTRA or 
candesartan affected them.  
Hypertension and atherosclerosis are disorders associated with inflammation 
[68]. We found that patients with ARAS have increased levels of 
inflammatory biomarkers and ET-1 compared to healthy controls. We also 
observed that these patients have an atherogenic lipoprotein profile in spite of 
ongoing treatment with statins. This abnormality was characterized by 
elevated levels of ApoC-III-containing lipoproteins. We speculate that these 
alterations may contribute to progressive atherosclerosis and an accelerated 
cardiovascular disease.  
We showed that IL-6 and ET-1 decreased after PTRA during the first month 
of follow-up suggesting beneficial effects of this intervention.  However, the 
potential consequences of reduced plasma levels of inflammatory biomarkers 
and ET-1 on clinically relevant outcomes clearly need to be examined 
further. Previous studies [125] have demonstrated that ARBs exert anti-
inflammatory effects, but in our study candesartan did not affect 
inflammatory biomarkers and ET-1 during 35 months follow up and hence 
did not support specific anti-inflammatory effects of ARBs in patients with 
ARVD. In addition, we observed that candesartan did not impair renal 
function and was well tolerated. It is feasible to speculate that RAAS-
blockade may attenuate disease progression in these patients although this 
was not observed in the present study. Naturally, a much larger study with a 
longer follow up would be needed to address this issue appropriately.  
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The lipoprotein abnormalities in ARVD patients observed in our study show 
similarities to the renal dyslipidemia described in patients with CKD and 
reduced GFR. How to effectively treat this dyslipidemia is still uncertain. A 
potentially effective therapy in patients with ARVD would be the 
combination of statins with fibrates. Fibrates and other peroxisome 
proliferator-activated receptor (PPAR) agonists have the potential to 
beneficially affect the catabolism of triglyceride-rich ApoB- and ApoC-III-
containing lipoproteins. Although PPAR agonists have the potential to 
correct dyslipidemia in ARVD, this hypothesis, and the impact on clinical 
outcomes need to be tested in clinical trials.  
During our studies, two large clinical trials: ASTRAL [31]  and CORAL [32] 
have been published. These studies have failed to show statistically 
significant benefits of revascularization, over optimal medical treatment, on 
blood pressure, kidney function, and cardiovascular outcomes. These two 
trials, despite their limitations, have influenced medical decision making 
away from invasive interventions [146, 147]. Patients with stable kidney 
function and adequate blood pressure control should not be considered for 
revascularization. Pharmacological management with antihypertensive 
agents, including ACEI/ARBs, antiplatelet drugs, cholesterol lowering 
therapy,  together with lifestyle modifications, remain the basic care for all 
patients with ARAS. But the conclusion of these trials should not be 
generalized to all patients with ARAS. For example, patients with recurrent 
episodes of flash pulmonary edema without an obvious cardiac cause, or with 
bilateral RAS or stenosis to a single functioning kidney combined with 
progressive renal impairment may be subject to intervention. Patients with a 
strong indication for treatment with RAAS-blockade, e.g. heart failure, who 
develop progressive renal failure during this treatment, may be also   
considered for intervention [146, 147].  
There is a need to accurately identify individuals who may benefit from renal 
revascularization. We found that plasma BNP levels are increased in patients 
with ARAS compared to healthy control, but that BNP could not be used to 
predict the outcome of PTRA on blood pressure. 
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